A5037656687- Phagocytosis and Immune Regulation
- Cancer Mechanisms and Therapy
- Enzyme function and inhibition
- Pancreatic function and diabetes
- Immune cells in cancer
Exelixis (United States)
2022
The multi-receptor tyrosine kinase inhibitor XL092 has been developed to inhibit the activity of oncogenic targets, including MET, VEGFR2, and TAM family kinases TYRO3, AXL MER. Presented here is a preclinical evaluation XL092. causes significant decrease in tumor MET phosphorylation (P < 0.01) murine Hs 746T xenograft models relative vehicle, 96% inhibition VEGFR2 lungs. Dose-dependent growth with was observed various models, dose-dependent regression seen NCI-H441 model. Tumor enhanced...
<p>Suppl Figure 2</p>
<p>Supplementary Figures and Tables with adjoining Legends</p>
<p>Suppl Figure 3</p>
<p>Suppl Figure 4</p>
<p>Suppl Figure 5</p>
<p>Suppl Figure 1</p>
<p>Suppl Figure 1</p>
<p>Suppl Figure 3</p>
<p>Suppl Figure 2</p>
<p>Suppl Figure 4</p>
<p>Suppl Figure 5</p>
<p>Supplementary Figures and Tables with adjoining Legends</p>
<div>Abstract<p>The multi-receptor tyrosine kinase inhibitor XL092 has been developed to inhibit the activity of oncogenic targets, including MET, VEGFR2, and TAM family kinases TYRO3, AXL MER. Presented here is a preclinical evaluation XL092. causes significant decrease in tumor MET phosphorylation (<i>P</i> < 0.01) murine Hs 746T xenograft models relative vehicle, 96% inhibition VEGFR2 lungs. Dose-dependent growth with was observed various models, dose-dependent...
<div>Abstract<p>The multi-receptor tyrosine kinase inhibitor XL092 has been developed to inhibit the activity of oncogenic targets, including MET, VEGFR2, and TAM family kinases TYRO3, AXL MER. Presented here is a preclinical evaluation XL092. causes significant decrease in tumor MET phosphorylation (<i>P</i> < 0.01) murine Hs 746T xenograft models relative vehicle, 96% inhibition VEGFR2 lungs. Dose-dependent growth with was observed various models, dose-dependent...